Therapeutic drug monitoring of the antimycobacterial drugs

Abstract

Because MDR tuberculosis and MAC are difficult to treat, TDM with the antimycobacterial drugs has become the standard of practice at NJC. By combining specific and sensitive assays, carefully collected samples, and clinical expertise, we are able to control and optimize antimycobacterial drug therapy. We continue to refine our approach with ongoing pharmacokinetic and pharmacodynamic research. Although such an array of services is not typical of most nonspecialized institutions, it is possible to follow the techniques described and to access our assay services. Furthermore, the elements of a good TDM service described can be applied to the TDM for any other disease state.